Bristol-Myers Squibb recently responded to a report from the Institute for Clinical and Economic Review (ICER) about determining value measurements for patients in the health industry.
The report, called “Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness, Value and Value-based Price Benchmarks,” highlights how many health professionals believe that health care communities should create an innovative atmosphere for providing better therapy research.
In Bristol-Myers Squibb’s response, the company emphasized that it is dedicated to prioritizing patients and families who are suffering from serious illnesses. The organization focuses on its immuno-oncology branch of research to change how cancer is treated. The goal is to broaden the company’s methods of offering long-term, meaningful outcomes.
Bristol-Myers Squibb recently made refractory or relapsed multiple myeloma a research priority. This cancer has a high unmet need: just 49 percent of multiple myeloma patients live for five or more years when they have received their diagnosis. Most of these patients have a relapse and remission cycle that can be difficult to break; when patients relapse for the first time, the second diagnosis can be worse than the original.
The goal of immuno-oncology therapies is to give patients long survival times and heightened quality of life. This is equally important for patients and their families.
To further help these patients, the company has developed Empliciti as a new option for treatments.
